Introduction 61
Proton pump inhibitors (PPIs) are commonly prescribed for gastrointestinal disorders, in 62 which the inhibition of gastric acid secretion is desirable, such as peptic ulcer disease, dyspepsia and 63 gastroesophageal reflux disease. The use of PPIs is widespread and has progressively increased since 64 their introduction. 1 In the ambulatory setting the prevalence of visits in which patients used PPIs 65 increased from 4.0% in 2002 to 9.2% in 2009. 2 Moreover, 63% of the patients using PPIs did not 66 have gastrointestinal complaints or a specific indication for PPI use. Accordingly, PPIs were included 67 among the most common potentially inappropriate medications, identified using the updated Beers 68 criteria. 3 For this reason, while prescribing this class of drugs, an accurate evaluation of the 69 risks/benefits ratio of long term use of PPI is formally recommended by the American 70 Gastroenterological Association. 4 In a Danish nationwide study, the prevalence of PPI use in adults 71 increased from 2% in 2002 to 7.4% in 2014 and prolonged treatment was very common. 5 Remarkably, 72 PPI use increased with age, its prevalence among patients over 60 years old reaching 14.0% in men 73 and 16.3% in women and exceeding 20% among patients aged 80 years and over. 5 In stage 5D chronic 74 kidney disease (CKD) patients, we found that PPI use is even higher, with 76 % of patients receiving 75 long-term treatment. 6 Bone and mineral disorders, including secondary hyperparathyroidism and 76 bone fractures, are more common among CKD patients than in people with normal renal function. 7 
77
In the general population, PPI use is associated with an increased risk of fractures. 8,9 78 The aim of this study was to assess the relationship between use of PPIs, and bone and hip 79 fractures in hemodialysis patients of the phases 2-4 of the observational Dialysis Outcomes and 80
Practice Patterns Study (DOPPS) study, which included the systematic collection of fractures 81 requiring hospitalization. 82
Material and Methods 83

Patient population 84
The DOPPS is a prospective cohort study of hemodialysis practices based on the collection of 85 observational longitudinal data for a random sample of patients from dialysis facilities in a 86 representative and random sample of units in more than twenty countries. 7 included the same DOPPS 1 countries, plus Australia, New Zealand, Canada, Belgium, and Sweden. 90
The DOPPS phases 2-4 included 34593 hemodialysis patients, of whom 27857 (i.e. 81%) were 91 hospitalized for various reasons. 92
Study groups, outcome and exposure definition 93
From a source population of 27857 hospitalized patients, 75 were excluded because of missing 94 baseline demographic characteristics (such as age, race, time of starting dialysis and gender) and 685 95 patients were excluded because of missing information on PPI treatment. Thus, 27097 hospitalized 96 patients were available for the present analysis. We specifically focused on hospitalized patients to 97 better capture medication data thus minimizing the possibility of information bias. 98
The DOPPS investigators identified all first hospitalizations (defined by an overnight hospital 99 stay) with an associated "bone fracture diagnosis code" according to international standards for 100 hospital admissions. Bone fractures were coded as either 'hip' or 'other'; information on other types 101 of fractures (e.g. vertebral fractures) were not available. Thus, bone fractures include "hip-fractures" 102 and fractures other than hip fractures. Hospitalizations and outpatient visits (including fracture-related 103 visits) occurring during the study, along with diagnoses and procedures (i.e. X-ray imaging) relevant 104 to the hospitalization or outpatient visit, were reported chronologically for each patient. Capturing 105 both hospitalization events and outpatient visits provided a reasonable expectation that the vast 106 majority of fracture-related events were recorded in this study. Hip fractures were distinguishable 107 from among all reported fracture-related events, whereas fracture types other than hip fracture were 108 less well defined and consequently analysed collectively. For fracture event rates, follow-up 109 continued until the first of death, fracture hospitalization, transplantation, renal replacement therapy 110 modality switch, recovery of renal function, departure from the facility, or end of follow-up. PPI use 111 was assessed on individual basis, i.e. whether or not the PPI was administered in the patient concerned at the time of the visit. Prevalent PPI users were those who were already treated with the drug at the 113 date of enrolment. Naïve users or "new users" were those who start the treatment after the enrolment 114 into the study. 115
Statistical Analysis 116
Patients' characteristics were summarized as mean ± standard deviation, median and inter-117 quartile range or as percent frequency, and comparisons between patients' groups were made by 118
independent T-Test, Mann-Whitney Test or Chi Square Test, as appropriate. The frequency of bone 119 and hip fractures requiring hospitalization across Countries was expressed as incidence rate 120 (fractures/100 person-years) and 95% confidence interval. In the 'time to the first event' survival 121 analyses, the index date for naïve PPI users was the date of starting treatment whereas for prevalent 122 PPI users and nonusers the index date was the date of enrollment. 123
The crude and adjusted relationships between PPI treatment and incidence rate of bone and 124 hip fractures, taking into account the competitive risk of mortality, were investigated by using the 125 cumulative incidence function and the Fine and Gray approach, 10 respectively. The effect of PPI on 126 study outcomes was also investigated by a cause-specific hazards Cox model dealing patient death as 127 a censoring event and stratifying by Country and study phase. To provide further insight into the 128 pathophysiological implications of study results, we calculated the etiological fraction or attributable 129 risk (AR), i.e. the proportion of fractures that would be prevented in our study cohort if the PPI 130 treatment was eliminated in treated patients. 131
In multiple Cox models, we included PPI treatment as well as a series of potential confounders 132 (i.e. all variables listed in Table 1) : age, gender, race, BMI, diabetes, smoking (past and current), 133 background CV comorbidities, dialysis vintage (i.e. the time spanning from the date of dialysis 134 initiation to the date of enrolment into the study), concomitant treatments (any form of Vitamin D, 135 phosphate binders, and calcium-based phosphate binders), and biochemical data [albumin, PTH, 136 calcium, phosphate, alkaline phosphatase and fractional urea clearance (Kt/V)]. To account for 137 prevalent users bias, a sensitivity analysis on naive patients versus no users was also performed.
Concomitant therapies (any form of Vitamin D, phosphate binders, and calcium-based phosphate 139 binders) were defined differentially for the two study outcomes, depending on the fact whether the 140 date of each specific treatment start precedes or not the date of the outcome occurrence. 141
Missing values for confounding variables were imputed by multiple imputation in which 30 142 completed data sets were generated and analyzed with standard combination rules for multiple 143 imputation. Each variable was used as a confounder in the imputation model. In Cox models fitted 144 according to the Fine and Gray approach, data were expressed as sub-distribution hazard ratios 145 (SHR), 95% CIs and P values. In cause-specific hazards Cox models dealing patient death as a 146 censoring event, stratifying by Country and study phase and matching patients of the two arms 147 according to the prescription time-distribution, 11 data were expressed as hazard ratios (HR), 95% CIs 148 and P values. 149
All analyses were performed by two standard statistical packages (SPSS for Windows Version 150 22, IBM, USA; STATA/IC 13.0 StataCorp P, TX, USA). 151
Role of the Funding source 152
None of the authors received any funding for this study. 153
Patient and Public Involvement 154
Full details about the involvement of patients and public in the DOPPS data collection are given 155 elsewhere (see https://www.dopps.org/). 156
Results 157
The main demographic, clinical and biochemical data of the whole study population 158 (n=27,097) as well as of PPI treated (n=13,283, 49%) and untreated (n=13,814, 51%) patients are 159 given in Table 1 . In individual countries, the prevalence of PPI treated patients ranges widely from 160
28.6% in Japan to 73.5% in Spain (Supplementary Figure 1) . Overall, patients from western 161 countries represent 77% of the PPI treated population and 60% of the non-PPI treated patients, while 162 the corresponding data for Asians are 12% and 28%. The incidence rates of bone fractures were higher 163 on average in PPI treated than in PPI untreated patients in all countries but Italy and Germany Figure 2) . However, in Italy hip fractures were higher in PPI treated than in 165 untreated patients whereas in Germany the contrary was observed. 166
(Supplementary
Across the follow-up period (median 19 months, IQR: 10-28 months), 1,592 patients 167 experienced bone fractures (3.8 bone fractures/100 person-years, 95% CI: 3.6-3.9) and 528 patients 168 had hip fractures (1.2 hip fractures/100 person-years, 95% CI: 1.1-1.3). Overall, 6,249 patients died. 169
The mortality rate was higher in PPI users than in no users (25.8% versus 20.4%, P<0.001) raising a 170 problem of competitive risks. In crude Cox models (Fine & Gray approach) taking into account the 171 competitive risk of mortality, the incidence rate of bone (SHR: 1.36, 95% CI: 1.24-1.51, P<0.001) 172 and hip fractures (SHR: 1.70, 95% CI: 1.43-2.02, P<0.001) was significantly higher in PPI treated 173 than in PPI untreated patients (Figure 1-upper 
panels). A sensitivity analysis in naïve PPI users 174
( Supplementary Table I) , confirmed a higher incidence rate of bone and hip fractures in PPI treated 175 than in PPI untreated patients (Figure 1-bottom panels) . The calculation of the attributable risk (AR) 176 showed an AR of 30% for bone fractures and 44% for hip fractures in the whole study population and 177 an AR of 37% and 52%, respectively, in the sensitivity analysis on naïve users versus untreated 178 suggesting that about one half of hip fractures and more than one third of bone fractures could be 179 avoided if PPI use was eliminated in treated patients. Data adjustment for potential confounders, i.e. 180 for all variables listed in Table 1 , did not materially affect the PPI-study outcomes links either in the 181 whole study cohort ('prevalent users + naïve users' versus 'no users', see Table 2 ) or in a sensitivity 182 analysis assessing the fractures risk of 'naïve users versus no users' ( Table 3) . 183
In multiple, country and phase stratified, cause-specific hazards Cox models (adjusting for the 184 same set of variables listed in Tables 2-3) in patients of the two arms matched according to the 185 prescription time (n=14136 of whom 3276 treated with PPI and 10860 untreated), PPI treatment 186 confirmed as a strong and independent risk factor of study outcomes [bone fractures, HR Country and 187 phase stratified: 1.47, 95% CI: 1.23-1.76, P<0.001; hip fractures, HR Country and phase stratified: 1.85, 95% CI: 188 1.37-2.50, P<0.001]. Of note, diabetes consistently emerged as a strong risk factor of bone and hip 189 fractures in the study population (see Tables 2-3 PPIs are among the most widely prescribed medications worldwide. The average prevalence 198 of PPI use in the DOPPS population is 49%, a figure markedly higher than that in the general 199 population, 6 where several studies have highlighted the association between PPI treatment and bone 200 fractures. 8, 9, 12 In a meta-analysis including 11 observational studies, 12 the reported relative risk for 201 hip fractures associated with PPI use was 1.30 (95 % CI: 1.19-1.43) and such an association was of 202 similar magnitude of that we found in the whole dialysis population comparing prevalent + naïve 203 users versus no users (SHR: 1.35, 95% CI: 1.13-1.62- Table 2 ) but lower than that emerged in the 204 sensitivity analysis comparing naïve users versus no users (SHR: 1.62, 95% CI: 1.24-2.11) indicating 205 that the prevalent users bias should be taken into account when investigating the effect of PPI on 206 adverse clinical outcomes in hemodialysis patients. In the same metanalysis, 12 the relative risk 207 associated with PPI users was also increased for spine (RR: 1.56, 95% CI 1.31-1.85) and any-site Indeed, a population-based study highlighted a relationship between bone fractures and an increased 214 risk of death and reported a mortality rate of 20% in the first year after a hip fracture. 14 Similar data on mortality associated with hip fractures were also reported in hemodialysis patients: post-fracture 216 mortality rates exceeded 500/1000 patient years and fractured patients had higher unadjusted rates of 217 death (3.7-fold) than the overall non-fractured dialysis population. 7 On the other hand, mortality is 218 exceedingly higher in hemodialysis patients than in the general population and for this reason it could 219 act as a competitive risk while investigating the relationship between PPI use and bone fractures. hypomagnesemia may worsen vascular calcifications in patients with CKD. 19 Interestingly, in the 239 DOPPS cohort treated with PPIs peripheral artery disease was more common (34% of patients) 240 compared to untreated patients (26%). Proton pump inhibitors interfere with the active transport of magnesium, and clinically significant phenomena are observed in the carriers of heterozygotic 242 mutations of the ion channels TRPM6 and TRPM7 (transient receptor potential melastatin), which 243 have a relevant role in the maintenance of magnesium homeostasis. 17, 19 Recently, Sakaguchi et al 244 investigated 113,683 patients undergoing hemodialysis over a 2-year follow-up, finding an incidence 245 of 2% for new hip fractures. The crude incidence rate was significantly higher among patients in the 246 lower quartiles of serum magnesium levels (2.63%, 2.08%, 1.76%, and 1.49% in Q1-Q4, 247 respectively). After adjustment for demographic and clinical factors, patients in Q1 had a 1.23-fold 248 higher risk for hip fracture than those in Q4 (95% confidence interval, 1.06 to 1.44; P=0.01). 20 Of 249 course, given the fact that we did not dose magnesium levels in the DOPPS patients, these 250 considerations, although biologically plausible, are purely speculative. 251
Vitamin B12 deficiency has been associated with PPI use. 21 Low vitamin B12 levels increase 252 homocysteine levels, impairing cross-linking of bone collagen, 22 and might increase the risk of bone 253 fractures. 23 In addition, peripheral neuropathy is also a consequence of vitamin B12 deficiency, 254 increasing the risk of falls and, consequently, of bone fractures. The association between PPI use and 255 increased risk of falls has been clearly demonstrated. 24 Moreover, a direct PPI action on bone is also 256 a possibility. 25 Osteoclast function is dependent on proton pumps, which may be directly inhibited by 257 PPIs, reducing bone resorption and turnover. This action was initially considered a potential treatment 258 for osteoporosis, 26 but altering bone turnover can deteriorate bone quality and increase the risk of 259 fractures. 260 PPI treatment has been associated with other relevant side effects, supporting the concept of 261 significant adverse biologic effects on the body, besides the intended effects in the gastrointestinal 262 system. 27 Microbiome alterations with bacterial overgrowth may affect absorption of nutrients, 263 including proteins and vitamin K, with potential long-term adverse effects on bone health and 264 increased fracture risk. 28 The potential interaction between PPIs and vitamin K is of interest, as 265 vitamin K intake is associated with a protective effect on bone fractures. 29 266 The large difference in the incidence rates of bone fractures among different countries, as well as the 267 finding that in Italian and German patients the side effect of PPI was not visible, remain unexplained 268 and they deserve further studies, in order to identify which factors might prevent bone fractures. 269
Study strengths and limitations 270
Strengths of our study are the large patient-population and the fact that the PPI-fractures 271 relationship remains significant in Cox models including potential confounders and taking into 272 account the competitive risk of death by the Fine and Gray approach 10 as well as in multiple, cause-273 specific hazards Cox models dealing patient death as a censoring event, stratifying by Country and 274 study phase and matching patients of the two arms according to the prescription time-distribution. 275 Furthermore, the potential distortion attributable to prevalent users' bias on the study results was 276 investigated by performing a detailed analysis in naïve patients versus no treated. Remarkably, such a 277 sensitivity analysis provides results even more convincing than those obtained in the whole study 278 population comparing prevalent + naïve PPI users versus no users. Lastly, the observational nature 279 of our cohort represents another strength, rather than a weakness, of our study, because observational 280 studies are recognized to be essential for investigating the safety profile of medications. 30 Although 281 in Cox models we adjusted for a series of well-known potential confounders (including demographic 282 and clinical variables and bone biomarkers), the possibility that we did not adjust for 'unmeasured 283 confounders' (including other tattribdrugs) cannot be excluded. However, the magnitude of the excess 284 risk of bone and hip fractures (ranging from +22% to +62%) in PPI treated patients as compared to 285 those untreated indicates that such a possibility is rather unlikely. Furthermore, it is important noting 286 that the hazard ratio of PPI for bone fractures we found in our study (see Table 2 ) was very similar 287 USA Renal Data System. This study shows that the odds ratio of hip fractures is higher in PPI treated 295 than in untreated patients, independently of a series of potential confounders. In the Vangala's study, 296 the adjusted excess risk of hip fractures of PPI use versus nonuse ranged from +16% to +21% 297 (dependent on the frequency of PPI administration), figures lower than those found by us in primary 298 (+35%) and sensitivity (+62% and +85%) analyses. This underestimation of the PPI effect on hip 299 fractures may depend on the fact that Vangala et al. 32 did not take into account the potential distortion 300 due to prevalent users bias, did not include into multivariate models circulating levels of bone 301 biomarkers and did not collect time to event data, all methodological issues which we specifically 302 considered in our study, which also has the strength of including an international cohort of 303 hemodialysis patients. 22(1.10-1.36), P<0.001  1.35(1.13-1.62) , P=0.001 02(1.01-1.02), P<0.001  1.04(1.03-1.05) 
Multiple Cox regression models taking into account the competing risk of death (Fine & Gray approach) Variables (units of increase)
Bone fractures SHR (95% CI) and P value PPI treatment (0=no users; 1=naïve users)  1.29(1.10-1.51), P=0.002  1.62(1.24-2.11) , P<0.001 Age (1 year)  1.02(1.02-1.03), P<0.001  1.06(1.04-1.07) 
Hip fractures SHR (95% CI) and P value
